Eli Lilly and Co. LLY, -0.50% said Wednesday a late-stage trial of a liver cancer treatment met its main goals. The company said patients in a phase 3 trial of Cyramza as a single agent in the second-line treatment of hepatocelluclar carcinoma, or liver cancer, met its primary endpoint of overall survival and the secondary endpoint of progression-free survival. "CYRAMZA has now demonstrated a survival benefit in four aggressive, difficult-to-treat tumor types in Phase 3 studies, including as a single agent in both gastric cancer and HCC," the company said in a statement. Eli Lilly is planning to start regulatory submissions in mid-2018. Shares were not yet active premarket, but have fallen about 10% in the last 12 months, while the S&P 500 SPX, -1.16% has gained 11%.